Novartis

Novartis, a pharmaceutical preparation manufacturing company headquartered in CH, has set ambitious climate targets. For 2025, the company reported total global emissions of approximately 4.38 billion kg CO2e, comprising approximately 192.3 million kg CO2e from Scope 1, and roughly 14.9 million kg CO2e from Scope 2 (market-based). Scope 3 emissions accounted for the largest portion, estimated at approximately 4.17 billion kg CO2e, with purchased goods and services being the most significant contributor within this scope.

Looking back, Novartis reported total global emissions of approximately 4.52 billion kg CO2e for 2024, and around 4.87 billion kg CO2e for 2023. In 2022, their total emissions were approximately 5.36 billion kg CO2e, and in 2021, they reported approximately 5.13 billion kg CO2e.

Novartis is committed to achieving carbon neutrality in its own operations (Scope 1 and 2) by 2025. Furthermore, the company has a net-zero target for its entire value chain by 2040. As part of its near-term goals, Novartis aims to reduce absolute Scope 1 and 2 GHG emissions by 90% by 2030, using a 2022 baseline. Additionally, they plan to reduce absolute Scope 3 GHG emissions by 42% within the same timeframe. For the long term, the commitment extends to achieving net-zero across the value chain by 2040, with a minimum 90% reduction in absolute Scope 1 and 2 emissions from 2030 through 2040, and a 90% reduction in absolute Scope 3 GHG emissions by 2040, also from the 2022 baseline.

Novartis's climate targets are validated by the Science Based Targets initiative (SBTi), aligning with the goal to limit global temperature increase to 1.5°C. They are also a signatory to the Climate Pledge.